Research Methods and Applications of Fibrinolytic Proteases: Thrombolysis, Fibrin Degradation, and Anticoagulant Evaluation
Research Methods and Applications of Fibrinolytic Proteases: Thrombolysis, Fibrin Degradation, and Anticoagulant Evaluation
Fibrinolytic proteases are commonly used to evaluate thrombolysis, fibrin degradation, and anticoagulation-related mechanisms. Research targets include plasmin, urokinase, streptokinase, lumbrokinase, nattokinase, and other natural or recombinant proteases.
Keywords: fibrinolytic protease; thrombolysis; fibrin degradation; plasmin; plasminogen; urokinase; streptokinase; lumbrokinase; nattokinase; fibrin plate method; clot lysis assay; fibrinogen degradation; anticoagulant activity; PT; APTT; TT; thrombin; coagulation factor Xa
1 Research Positioning of Fibrinolytic Proteases
1.1 Basic Concepts
(1) Fibrinolytic proteases
Fibrinolytic proteases refer to proteases that can directly degrade fibrin or indirectly promote fibrin cleavage by activating plasminogen. The research focus is not simply to determine whether they have “protease activity,” but to confirm whether they can produce a measurable lytic effect in fibrin clots, plasma clots, or thrombus models.
(2) Thrombolysis and fibrin degradation
After thrombus formation, the fibrin network constitutes the stable structure of the thrombus. Fibrinolytic proteases loosen the clot structure by cleaving fibrin or initiating plasmin generation, thereby releasing fibrin degradation products. In experiments, it is necessary to distinguish among three types of effects: direct fibrin degradation, plasminogen activation, and inhibition of the coagulation process.
(3) Positioning in anticoagulation research
Anticoagulation mainly refers to inhibition of thrombin generation, fibrin formation, or the coagulation factor cascade. Some fibrinolytic proteases may affect both coagulation and fibrinolysis, for example by reducing fibrinogen levels, prolonging coagulation time, or interfering with clot formation. Therefore, anticoagulant evaluation should be designed separately from fibrinolytic evaluation.
1.2 Research Application Scenarios
(1) Screening of thrombolytic activity
Natural proteases, recombinant proteases, fermentation products, and enzymatic fractions are often screened using the fibrin plate method, plasma clot lysis assay, or whole-blood clot lysis assay. At the screening stage, the main readouts include lysis zone size, clot mass change, lysis time, and dose-response effects.
(2) Analysis of fibrin degradation mechanisms
To prove that a protease directly cleaves fibrin, fibrinogen degradation bands, cross-linked fibrin degradation products, fibrinopeptide release, D-dimer, changes in fibrin gel structure, and cleavage fragments can be detected. This part is more focused on mechanism validation rather than simple activity screening.
(3) Evaluation of anticoagulation and coagulation regulation
Anticoagulation research usually detects thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), activated clotting time (ACT), fibrinogen level, thrombin activity, FXa activity, and coagulation activation markers. If a protease mainly dissolves preformed clots but does not affect the coagulation cascade, it should not be simply described as an anticoagulant protease.
Table 1 Differences Among Fibrinolysis, Fibrin Degradation, and Anticoagulant Effects
Research direction | Main target | Common readouts | Key interpretation |
Fibrinolytic activity | Preformed fibrin clot or thrombus | Lysis zone, clot mass reduction, lysis time | Determines whether the sample promotes clot lysis |
Fibrin degradation | Fibrin, fibrinogen, and cross-linked fibrin network | Degradation bands, FPA, FPB, FDP, D-dimer | Determines whether fibrin structures are cleaved directly or indirectly |
Plasminogen activation | Plasminogen | Plasmin generation, substrate hydrolysis, enhanced clot lysis | Determines whether the effect depends on the plasminogen-plasmin system |
Anticoagulant activity | Coagulation factors, thrombin, FXa, fibrin formation process | PT, APTT, TT, ACT, coagulation factor levels | Determines whether the coagulation cascade or fibrin formation is inhibited |
Coagulation activation status | Thrombin generation and common pathway activation | F1+2, TAT, thrombin level | Determines whether the coagulation system is activated or inhibited |
2 Source Types of Fibrinolytic Proteases
2.1 Proteases Related to the Endogenous Fibrinolytic System
(1) Plasmin
Plasmin is the core effector protease in the fibrinolytic system and can directly cleave fibrin and fibrinogen. Its precursor is plasminogen, which is converted into active plasmin by tPA, uPA, and other activators. Plasmin has a broad substrate range and may degrade not only fibrin but also some extracellular matrix proteins and plasma proteins.
(2) Tissue-type plasminogen activator
Tissue-type plasminogen activator (tPA) mainly produces plasmin by activating plasminogen. Its activity is enhanced in the presence of fibrin, making it more oriented toward fibrin-dependent fibrinolysis. In research, tPA is often used as a positive control, for fibrinolytic pathway validation, and for comparison of thrombolytic mechanisms.
(3) Urokinase-type plasminogen activator
Urokinase-type plasminogen activator (uPA) activates plasminogen and is closely associated with cell-surface uPAR, cell migration, matrix remodeling, and tumor invasion. In thrombolysis research, uPA can represent plasminogen-activating proteases; in tissue remodeling research, it is often regarded as an important node in extracellular proteolytic systems.
2.2 Microbial-Derived Fibrinolytic Proteases
(1) Streptokinase
Streptokinase is not a typical protease by itself. Instead, it promotes plasmin generation by forming a complex with plasminogen. Its fibrinolytic effect depends on plasminogen. Therefore, experimental designs should include both “plasminogen-containing” and “plasminogen-free” systems to distinguish direct degradation from activation-type fibrinolysis.
(2) Staphylokinase
Staphylokinase (SAK) is also a plasminogen activation-related protein and can promote the conversion of plasminogen to plasmin. Its mechanism research focuses on plasminogen dependence, reaction efficiency on the fibrin surface, and the influence of plasma inhibitors.
(3) Nattokinase
Nattokinase is a common microbial-derived fibrinolytic protease, mainly derived from fermentation products of Bacillus subtilis. Studies usually focus on fibrin plate lysis zones, fibrinogen degradation, plasma clot lysis, and changes in fibrinolytic indicators after oral intake. Because fermentation-derived samples may contain multiple proteases and small-molecule components, purification level and activity unit standardization are very important.
2.3 Animal-Derived and Natural Fibrinolytic Proteases
(1) Lumbrokinase enzyme systems
Lumbrokinase usually refers to a multi-component fibrinolytic protease system derived from earthworms. It may directly degrade fibrin and indirectly affect the fibrinolytic system. Because it is often an enzyme system or a mixed protein fraction, research should focus on component separation, activity standardization, molecular weight distribution, and batch-to-batch consistency.
(2) Snake venom and leech-related proteases
Some snake venom proteases can cleave fibrinogen or affect coagulation factors, showing anticoagulant, defibrinogenating, or bidirectional procoagulant/anticoagulant effects. Leech-derived components often include thrombin inhibitors, anticoagulant components, and platelet-related regulatory components. Such samples have complex mechanisms, so not all “clot reduction” results should be interpreted as enhanced fibrinolysis.
(3) Plant-derived proteases
Plant proteases such as bromelain and papain can degrade various protein substrates and may show fibrin or fibrinogen degradation capacity in vitro. However, their substrate specificity is broad. If used in thrombolysis research, substrate selectivity, safety, and the risk of nonspecific protein degradation should be carefully evaluated.
Table 2 Source Types and Research Focuses of Fibrinolytic Proteases
Source type | Representative targets | Main mode of action | Research focus |
Endogenous fibrinolytic system | Plasmin, tPA, uPA | Direct fibrin cleavage or plasminogen activation | Fibrinolytic pathway mechanism, positive controls, standardized models |
Microbial sources | Streptokinase, staphylokinase, nattokinase | Plasminogen activation or direct fibrin degradation | Fermentation screening, purification identification, activity unit establishment |
Animal sources | Lumbrokinase, snake venom proteases, leech-related components | Fibrinolysis, anticoagulation, defibrinogenation, or multi-target regulation | Component complexity, mechanism of action, and safety evaluation |
Plant sources | Bromelain, papain, etc. | Broad-spectrum proteolysis | Substrate specificity, fibrin selectivity, and nonspecific degradation risk |
Recombinant proteases | Recombinant tPA, recombinant uPA, engineered fibrinolytic proteins | Clear mechanism and standardizable | Efficacy evaluation, structural modification, targeted delivery research |
3 Mechanisms of Thrombolysis and Fibrin Degradation
3.1 Plasminogen-Plasmin System
(1) Pathway initiation
Plasminogen is converted into plasmin under the action of tPA, uPA, or other activators. Plasmin then cleaves the fibrin network and gradually loosens the clot. tPA has high efficiency on the fibrin surface and is suitable for studying fibrin-dependent fibrinolysis, whereas uPA is more commonly associated with cell-surface proteolysis, migration, and matrix remodeling.
(2) Fibrin binding
Fibrin is not only a substrate for plasmin but also a platform for enrichment of plasminogen and tPA. Binding to the fibrin surface can improve local fibrinolytic efficiency and concentrate proteolysis on the clot structure. If an experimental system lacks fibrin or plasminogen, the effects of some activation-type enzymes may be underestimated or not observed.
(3) Inhibitory regulation
The fibrinolytic system is regulated by inhibitors such as PAI-1, α2-antiplasmin, and TAFI. PAI-1 inhibits tPA and uPA, α2-antiplasmin neutralizes free plasmin, and TAFI reduces lysine-binding sites on the fibrin surface. In plasma systems, these inhibitors significantly affect fibrinolysis assay results.
3.2 Direct Fibrin Degradation
(1) Fibrin cleavage
Some proteases can directly cleave the fibrin network without relying on plasminogen. Such enzymes can still form lysis zones on plasminogen-free fibrin plates or cause mass loss and structural disruption in purified fibrin clots. Direct degradation capacity is suitable for validation using purified fibrin systems.
(2) Fibrinogen degradation
Many fibrinolytic proteases can also degrade fibrinogen. Fibrinogen degradation affects clot formation and may appear as prolonged thrombin-induced clotting time, reduced gel strength, or a sparse fibrin network. Research must distinguish between “dissolving a preformed clot” and “preventing clot formation.”
(3) Cross-linked fibrin degradation
Fibrin in mature thrombi is often cross-linked by FXIIIa and has a more stable structure. A protease that can degrade non-cross-linked fibrin may not necessarily degrade cross-linked fibrin effectively. For thrombolysis research, cross-linked fibrin clots, plasma clots, or whole-blood clot models should be prioritized over simple fibrinogen substrates.
3.3 Intersection Between Anticoagulation and Fibrinolysis
(1) Thrombin inhibition
If a protease or its component inhibits thrombin, fibrin generation can be reduced, resulting in prolonged TT or weakened clot formation. This belongs to the direction of anticoagulation or thrombin inhibition and is not equivalent to enhanced fibrinolysis.
(2) Fibrinogen consumption
Some proteases degrade fibrinogen, leading to insufficient clot formation. This may appear as decreased fibrinogen levels, reduced clot strength, and prolonged coagulation time. Such results should be described as defibrinogenating-like effects or fibrinogen degradation effects.
(3) Regulation of coagulation factors
If a sample affects FXa, FVIIa, FXIa, FXIIa, or other coagulation factors, it can alter thrombin generation and clot formation speed. This type of effect belongs to coagulation pathway regulation and should be verified using coagulation factor activity, PT, APTT, F1+2, TAT, or related indicators.
Table 3 Mechanisms of Fibrinolytic Proteases and Experimental Differentiation
Mechanism | Typical manifestation | Recommended validation method | Interpretation focus |
Direct fibrin degradation | Lysis zone still forms in a plasminogen-free system | Plasminogen-free fibrin plate, purified clot degradation | Indicates the protease can directly cleave fibrin |
Plasminogen activation | Fibrinolysis is enhanced in the presence of plasminogen | Add plasminogen and detect plasmin substrate hydrolysis | Indicates dependence on the plasminogen-plasmin system |
Fibrinogen degradation | Clot formation is weakened or delayed | Fibrinogen SDS-PAGE, TT, FIB detection | Must be distinguished from thrombolysis |
Inhibition of thrombin or coagulation factors | PT, APTT, or TT is prolonged | Coagulation function assays, thrombin/FXa activity assays | Anticoagulant mechanism, not equivalent to fibrinolysis |
Altered coagulation activation status | Changes in F1+2, TAT, and other markers | Coagulation activation marker detection | Reflects thrombin generation and common pathway activation |
4 Methods for Detecting Fibrinolytic Activity
4.1 Fibrin Plate Method
(1) Method principle
The fibrin plate method forms a gel from fibrinogen and thrombin, then adds the test protease into wells or onto filter papers for incubation. If the sample has fibrinolytic activity, a transparent lysis zone forms on the plate. The diameter or area of the lysis zone can serve as a preliminary activity indicator.
(2) Method types
Plasminogen-containing plates are suitable for detecting plasminogen-activating samples, such as uPA, streptokinase, or staphylokinase-like effects. Plasminogen-free plates are suitable for detecting direct fibrin degradation capacity. The results of both plate types are critical for mechanistic interpretation and should not be replaced by only one system.
(3) Application boundaries
This method is intuitive and suitable for initial screening, but it is strongly affected by diffusion rate, molecular weight, sample concentration, gel thickness, and incubation time. A larger lysis zone does not necessarily indicate stronger in vivo thrombolytic ability, so further validation using clot models and plasma systems is required.
4.2 Clot Lysis Assays
(1) Purified fibrin clot
Purified fibrin clots are constructed from fibrinogen and thrombin. The system is simple and suitable for studying direct fibrin degradation. Degradation can be evaluated by clot mass reduction, turbidity changes, or released protein detection.
(2) Plasma clot
Plasma clots contain fibrinogen, coagulation factors, plasminogen, and endogenous inhibitors, making them closer to a physiological clot environment. This system can reflect fibrinolytic effects in a complex plasma background, but mechanistic interpretation is also more complicated.
(3) Whole-blood clot
Whole-blood clots contain red blood cells, platelets, plasma proteins, and fibrin networks, making them closer to real thrombus structures. Common readouts include clot weight change, hemoglobin release, clot retraction, and lysis time. This model is suitable for application evaluation but should not be used as the only mechanistic evidence.
4.3 Detection of Fibrinogen Degradation
(1) SDS-PAGE analysis
After incubating the test protease with fibrinogen, SDS-PAGE is used to observe degradation of the Aα, Bβ, and γ chains. Different proteases differ in the sequence and speed of degradation of the three chains, which can be used to assess substrate preference and degradation pattern.
(2) Fibrinopeptide detection
Thrombin cleavage of fibrinogen releases fibrinopeptide A and fibrinopeptide B. Detection of FPA and FPB can help determine thrombin action, fibrin formation, and fibrinogen conversion status.
(3) Gel-forming capacity
If fibrinogen is pre-degraded and then thrombin is added to form a clot, clot formation time, gel strength, and turbidity curves change. This method is suitable for evaluating whether a sample affects coagulation by disrupting fibrinogen.
4.4 Chromogenic Substrates and Coagulation Readouts
(1) Fibrinolytic system substrates
Chromogenic substrates can be used to detect urokinase, plasmin-like activity, or plasminogen activation reactions. This method is sensitive and convenient for kinetic analysis, but short peptide substrates do not fully represent fibrin network degradation capacity.
(2) Coagulation function readouts
PT, APTT, TT, and ACT can determine whether a sample affects the coagulation process at an overall level. If a fibrinolytic protease both prolongs TT and degrades fibrinogen, this suggests a possible defibrinogenating-like effect.
(3) Coagulation activation markers
F1+2 and TAT reflect thrombin generation and coagulation system activation. In anticoagulation research, coagulation time alone is insufficient to resolve mechanisms, and coagulation factors, thrombin, and antithrombin-related indicators should be interpreted together.
Table 4 Comparison of Fibrinolytic Activity Detection Methods
Method | Sample applicability | Main readout | Advantage | Limitation |
Fibrin plate method | Enzyme solutions, fermentation broth, purified proteins | Lysis zone diameter or area | Intuitive and suitable for initial screening | Strongly affected by diffusion; limited quantification |
Purified fibrin clot lysis | Purified enzymes, candidate proteases | Clot mass, turbidity, released proteins | Suitable for direct degradation validation | Insufficient physiological complexity |
Plasma clot lysis | Drugs, enzyme preparations, plasma systems | Clot lysis rate, time curve | Closer to body-fluid environment | Affected by endogenous inhibitors |
Whole-blood clot lysis | Antithrombotic candidates | Clot mass, hemoglobin release | Closer to thrombus structure | Mechanistic interpretation is complex |
Fibrinogen degradation SDS-PAGE | Purified proteases, enzyme fractions | Aα/Bβ/γ chain degradation | Can determine substrate preference | Does not directly represent thrombolysis |
Chromogenic substrate method | Purified enzymes, kinetic studies | Absorbance change | Sensitive and suitable for kinetics | Short peptide substrates are not equivalent to fibrin networks |
5 Evaluation Systems in Anticoagulation Research
5.1 Routine Coagulation Indicators
(1) PT
Prothrombin time (PT) mainly reflects changes in the extrinsic coagulation pathway and the common pathway. If PT is prolonged after treatment with a fibrinolytic protease, it may indicate effects on the tissue factor pathway, coagulation factor activity, or thrombin generation in the common pathway.
(2) APTT
Activated partial thromboplastin time (APTT) mainly reflects the intrinsic coagulation pathway and the common pathway. If APTT is prolonged, attention should be paid to whether FXII, FXI, FIX, FVIII, and common pathway factors are affected.
(3) TT
Thrombin time (TT) reflects the process by which thrombin converts fibrinogen into fibrin. If TT is significantly prolonged, it often suggests inhibition of thrombin activity, decreased fibrinogen concentration, or destruction of fibrinogen structure.
5.2 Coagulation Factor- and Thrombin-Related Assays
(1) Thrombin activity
Some proteases or natural products can directly inhibit thrombin activity, resulting in reduced fibrin formation. This mechanism should be further verified using thrombin substrates, thrombin levels, thrombin-antithrombin complexes, or thrombin generation assays.
(2) FXa activity
FXa is a key node in the common coagulation pathway. If a sample inhibits FXa activity, thrombin generation may be reduced. In anticoagulation research, FXa activity can serve as a supplementary indicator.
(3) Endogenous anticoagulant factors
Antithrombin III can inhibit thrombin, FXa, and other key coagulation enzymes. If the effect of a sample on the anticoagulant system is being studied, AT-III levels, TAT complexes, and coagulation factor changes can be detected simultaneously.
5.3 Application Evaluation from In Vitro to In Vivo
(1) Plasma and whole-blood systems
After results in purified systems are clarified, testing should proceed to plasma clot or whole-blood clot models. This stage is closer to the actual thrombus environment and can evaluate the effects of endogenous inhibitors, plasma proteins, and cellular components on thrombolysis.
(2) Bleeding risk
Proteases with strong fibrinolytic or anticoagulant effects may increase bleeding risk. In application research, coagulation time, fibrinogen levels, coagulation factor levels, and tissue bleeding indicators should be detected. Clot lysis rate alone should not be pursued.
(3) Stability and specificity
Candidate proteases also require evaluation of pH stability, temperature stability, plasma stability, protease inhibitor sensitivity, and substrate selectivity. Broad-spectrum proteases with poor fibrin selectivity may show strong in vitro lytic effects but have higher application risk.
Table 5 Common Indicators in Anticoagulant and Antithrombotic Research
Indicator | Main reflection | Applicable question | Interpretation focus |
PT | Extrinsic coagulation pathway | Whether the tissue factor pathway or common pathway is affected | Prolongation is not equivalent to enhanced fibrinolysis |
APTT | Intrinsic coagulation pathway | Whether intrinsic coagulation factors are affected | Can indicate the direction of anticoagulant action |
TT | Thrombin-fibrinogen conversion | Whether thrombin or fibrinogen is affected | Sensitive to fibrinogen degradation |
ACT | Overall clotting time | Whether coagulation is globally delayed | Suitable for preliminary anticoagulant effect evaluation |
FIB | Fibrinogen concentration | Whether defibrinogenating activity exists | Should be combined with band or chain-specific detection |
FPA/FPB | Fibrin formation process | Whether thrombin cleavage of fibrinogen occurs | Suitable for coagulation activation evaluation |
F1+2 | Thrombin generation | Whether coagulation system activation occurs | Helps analyze anticoagulant mechanisms |
TAT | Thrombin-antithrombin complex | Thrombin generation and endogenous anticoagulant response | Suitable for plasma or animal model evaluation |
FXa | Upstream node of the common pathway | Whether thrombin generation is affected | Suitable for anticoagulant mechanism analysis |
6 Product Selection for Fibrinolytic Protease Research
Table 6 Product Selection for Fibrinolytic Protease, Fibrin Degradation, and Anticoagulation Research
Cat. No. | Product Name | Grade/Specification | Product category | Application positioning |
Plasmin from Human Plasma | Native,EnzymoPure™,≥90%(SDS-PAGE),≥15 U/mg protein; Protein concentration: See COA | Fibrinolytic effector enzyme / positive control | Used for fibrin degradation, clot lysis, fibrinolytic positive control, and substrate validation | |
Plasmin, Human Plasma, Lyophilized |
| Fibrinolytic effector enzyme / positive control | Used for plasmin-mediated fibrin cleavage, clot lysis, and methodological controls | |
Plasminogen from human plasma | Bioactive, ActiBioPure™, High Performance, EnzymoPure™, ≥95%(SDS-PAGE), ≥120 U/mg protein | Plasminogen system component | Used to construct fibrinolytic systems involving tPA, uPA, streptokinase, staphylokinase, and other plasminogen activators | |
Urokinase from human urine | EnzymoPure™, ≥85%, Potency ≥50000IU/mg，specific activeiy 120000IU/mg | Plasminogen activator | Used for uPA-mediated plasminogen activation, plasma clot lysis, and fibrinolytic pathway positive controls | |
Streptokinase， from β-hemolytic Streptococcus (Lancefield Group C) | EnzymoPure™, ≥2,000 units/mg | Plasminogen activation-related protein | Used for plasminogen-dependent thrombolysis models and mechanistic control of microbial fibrinolysis | |
Staphylokinase (SAK) | Animal Free,Carrier Free,Bioactive,Recombinant,ActiBioPure™,High Performance,≥90%(SDS-PAGE),≥50000 U/mg protein | Plasminogen activation-related protein | Used for SAK-mediated plasminogen activation, thrombolysis, and activation-type fibrinolytic mechanism research | |
Lumbrokinase | ActiBioPure™, Bioactive, High Performance, EnzymoPure™, Native, ≥38000 U/mg powder | Natural fibrinolytic protease | Used for lumbrokinase-type fibrinolytic activity, fibrin degradation, and in vitro clot lysis research | |
Lumbrokinase | EnzymoPure™, ≥12000U/mg | Natural fibrinolytic protease | Used for lumbrokinase activity comparison, batch evaluation, and clot lysis model validation | |
Nattokinase | Bioactive,ActiBioPure™,High Performance,EnzymoPure™,from Bacillus subtilis; ≥40000 FU/g enzyme powder | Microbial-derived fibrinolytic protease | Used for nattokinase fibrinolytic activity evaluation, fibrin plate assays, and clot lysis experiments | |
Nattokinase | Bioactive,ActiBioPure™,High Performance,EnzymoPure™,from Bacillus subtilis; ≥20000 FU/g enzyme powder | Microbial-derived fibrinolytic protease | Used for activity comparison and methodological validation of fermentation-derived fibrinolytic proteases | |
SK 216 | ≥98%(HPLC) | Fibrinolytic regulatory small molecule | Used for PAI-1 inhibition, enhancement of tPA/uPA fibrinolytic pathways, and mechanism validation of fibrinolytic inhibition release | |
Alpha 2 Antiplasmin from Human Plasma | BioReagent, Native, ≥95%(SDS-PAGE), Pre-lyophilization Protein Concentration | Fibrinolytic inhibitor | Used to evaluate the inhibitory effect of α2-antiplasmin on plasmin activity, fibrin cleavage, and clot lysis | |
Z-GGR-pNA Urokinase Substrate (chromogenic) | ≥98% | Fibrinolytic activity chromogenic substrate | Used for urokinase/uPA activity detection, enzyme kinetic analysis, and plasminogen activation system evaluation | |
Tranexamic acid-d-1 | ≥99% | Antifibrinolytic mechanism control reagent | Used for antifibrinolytic mechanism studies, fibrinolysis inhibition controls, or labeled compound methodological analysis | |
Fibrin |
| Fibrin degradation substrate | Used for direct fibrin degradation experiments, plasmin activity validation, and clot model construction | |
Fibrinogen，Bovine Plasma | 50-70% protein (≥85% of protein is clottable) | Fibrinogen and clot construction substrate | Used for fibrin plates, fibrin clot construction, and fibrinogen degradation experiments | |
fibrinogen | Moligand™ | Fibrinogen-related research reagent | Used for fibrinogen binding, fibrin formation, and protease substrate-related mechanism research | |
fibrinogen alpha chain | Moligand™ | Fibrinogen chain research reagent | Used for FGA-chain-related detection, degradation fragment analysis, and chain-specific mechanism research | |
fibrinogen beta chain | Moligand™ | Fibrinogen chain research reagent | Used for FGB-chain-related detection, degradation fragment analysis, and chain-specific mechanism research | |
fibrinogen gamma chain | Moligand™ | Fibrinogen chain research reagent | Used for FGG-chain-related detection, cross-linked fibrin research, and chain-specific analysis | |
[Glu1] Fibrinopeptide B, human | ≥98% | Fibrinopeptide standard / research reagent | Used for fibrinopeptide B release, thrombin cleavage site research, and fibrin formation process studies | |
Fibrinopeptide B, human | ≥97%(HPLC) | Fibrinopeptide standard / research reagent | Used for FPB-related detection, fibrin formation, and coagulation activation process analysis | |
Fibrinopeptide A, human TFA | ≥95% | Fibrinopeptide standard / research reagent | Used for FPA-related detection and evaluation of thrombin-mediated fibrinogen cleavage | |
Recombinant Fibrinogen alpha chain Antibody | Recombinant, ExactAb™, Validated, See COA | Fibrinogen chain antibody | Used to detect FGA chain expression, degradation fragments, and fibrinogen structural changes | |
Fibrinogen beta chain Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA | Fibrinogen chain antibody | Used for FGB chain detection, fibrinogen degradation, and clot substrate integrity analysis | |
Fibrinogen gamma chain Mouse mAb | Carrier Free, ExactAb™, Validated, 1.0 mg/mL | Fibrinogen chain antibody | Used for FGG chain detection, cross-linked fibrin-related research, and degradation fragment analysis | |
Human Fibrinogen (Fbg) ELISA Kit | BioReagent | Fibrinogen detection ELISA | Used for detecting fibrinogen levels in human samples and evaluating changes in fibrin formation substrate | |
Human Fibrinogen Alpha (FGα) ELISA Kit | BioReagent | Fibrinogen detection ELISA | Used for human FGA chain detection and auxiliary analysis of chain-specific fibrinogen degradation | |
Human Fibrinogen Beta (FGB) ELISA Kit | BioReagent | Fibrinogen detection ELISA | Used for human FGB chain detection and auxiliary evaluation of fibrinogen degradation patterns | |
Human Fibrinogen Gamma (FGγ) ELISA Kit | BioReagent | Fibrinogen detection ELISA | Used for human FGG chain detection and suitable for cross-linked fibrin and clot structure research | |
Human Fibrinopeptide A (FPA) ELISA Kit | BioReagent | Fibrin formation marker ELISA | Used to detect FPA release and evaluate thrombin-mediated fibrinogen cleavage | |
Human Fibrinopeptide B (FPB) ELISA Kit | BioReagent | Fibrin formation marker ELISA | Used to detect FPB release and assist evaluation of fibrin formation and coagulation activation | |
Rat Fibrinogen (Fbg) ELISA Kit | BioReagent | Fibrinogen detection ELISA | Used for Fbg detection in rat thrombosis, coagulation, and fibrinolysis models | |
Rat Fibrinopeptide A (FPA) ELISA Kit | BioReagent | Fibrin formation marker ELISA | Used for evaluating coagulation activation, FPA release, and fibrin formation in rats | |
Rat Fibrinopeptide B (FPB) ELISA Kit | BioReagent | Fibrin formation marker ELISA | Used for rat FPB release detection and coagulation process analysis | |
Mouse Fibrinogen (Fbg) ELISA Kit | BioReagent | Fibrinogen detection ELISA | Used for Fbg detection in mouse thrombosis, coagulation, inflammation, and fibrinolysis models | |
Mouse Fibrinopeptide A (FPA) ELISA Kit | BioReagent | Fibrin formation marker ELISA | Used for evaluating FPA release, thrombin activation, and fibrin formation in mice | |
Thrombin | Bioactive,ActiBioPure™,Native,High Performance,EnzymoPure™,from human plasma; 400-1000 NIH U/mg protein | Clot construction enzyme | Used for converting fibrinogen into fibrin, constructing in vitro clots, and thrombin activity controls | |
Liquid — High Purity Thrombin (> 2700 U/mg Protein) | EnzymoPure™, ＞ 500 units/ml | Clot construction enzyme | Used for high-activity thrombin reaction systems, fibrin clot preparation, and methodological validation | |
High Purity Bovine Thrombin (> 2200 U/Mg Protein) | EnzymoPure™, ＞ 200,000 units/g powder | Clot construction enzyme | Used for fibrinogen clotting, clot preparation, and thrombin control systems | |
Bovine Prothrombin | EnzymoPure™, 50,000 - 150,000 units/g powder | Thrombin generation system reagent | Used for thrombin generation, coagulation pathway research, and anticoagulant mechanism studies | |
Bovine Lung Thromboplastin | EnzymoPure™, ＞1200 units/mg powder | Extrinsic coagulation pathway reagent | Used for PT-related systems, prothrombin activation, and extrinsic coagulation pathway research | |
Factor Xa | Bioactive,ActiBioPure™,Native,High Performance,EnzymoPure™,from human plasma; Protein concentration: See COA | Anticoagulant mechanism target enzyme | Used for FXa activity detection, common coagulation pathway evaluation, and anticoagulant mechanism validation | |
Factor VIIa | Bioactive,ActiBioPure™,Native,High Performance,EnzymoPure™,≥95%(SDS-PAGE),from human plasma; Protein concentration: See COA | Anticoagulant mechanism target enzyme | Used for extrinsic coagulation pathway, FVIIa activity, and anticoagulant mechanism research | |
Factor XIa | Bioactive,ActiBioPure™,Native,High Performance,EnzymoPure™,≥95%(SDS-PAGE),from human plasma; Protein concentration: See COA | Anticoagulant mechanism target enzyme | Used for intrinsic coagulation pathway, FXIa activity, and anticoagulant candidate evaluation | |
Factor XIIa Beta | BioReagent,Native,from human plasma; Protein concentration: See COA | Anticoagulant mechanism target enzyme | Used for contact activation pathway, FXIIa-related coagulation initiation, and anticoagulant mechanism research | |
Antithrombin III from Human Plasma | BioReagent, Native, ≥95%(SDS-PAGE), Pre-lyophilization Protein Concentration | Endogenous anticoagulant factor | Used for AT-III-mediated thrombin/FXa inhibition and anticoagulation regulatory mechanism research | |
Prothrombin Time (PT) Assay Kit (One-Stage Method) | BioReagent | Coagulation function assay kit | Used to evaluate changes in the extrinsic coagulation pathway and common pathway and to help distinguish anticoagulant effects from fibrinolytic effects | |
Activated Partial thromboplastin Time Assay Kit | BioReagent | Coagulation function assay kit | Used to evaluate the intrinsic coagulation pathway and anticoagulant activity of candidate samples | |
Thrombin Time (TT) Assay Kit | BioReagent | Coagulation function assay kit | Used to evaluate the thrombin-fibrinogen conversion process and the influence of fibrinogen degradation | |
Activated Clotting Time (ACT) Assay Kit (Coagulation Method) | BioReagent | Coagulation function assay kit | Used for overall clotting time evaluation and anticoagulant effect detection | |
Human Coagulation Factor Ⅱ(FⅡ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for detecting human prothrombin/coagulation factor II and evaluating the common coagulation pathway | |
Human Coagulation Factor Ⅶ (FⅦ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for evaluating the extrinsic coagulation pathway | |
Human Coagulation Factor Ⅹ (F10) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for FX level detection and common coagulation pathway analysis | |
Human Coagulation Factor Ⅺ (FⅪ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for intrinsic coagulation pathway and FXI level detection | |
Human Coagulation Factor Ⅻ(FⅫ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for contact activation pathway and FXII level detection | |
Human Activated Coagulation Factor VIIa(FVIIa) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for detecting FVIIa activation status and studying the extrinsic coagulation pathway | |
Human Coagulation Factor Ⅺa(FⅪa) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for detecting FXIa activation status and evaluating intrinsic coagulation activation | |
Human Prothrombin Fragment 1+2 (F1+2) ELISA Kit | BioReagent | Coagulation activation marker ELISA | Used to evaluate thrombin generation and coagulation system activation | |
Human Thrombin/antithrombin Complex(TAT) ELISA Kit | BioReagent | Coagulation activation marker ELISA | Used to analyze thrombin generation, AT-III binding, and coagulation activation status | |
Human Thrombin ELISA Kit | BioReagent | Thrombin detection ELISA | Used for detecting human thrombin levels and evaluating thrombin-related anticoagulant mechanisms | |
Human Antithrombin Ⅲ(AT-Ⅲ) ELISA Kit | BioReagent | Anticoagulant factor ELISA | Used for detecting AT-III levels and evaluating endogenous anticoagulant status | |
Rat Coagulation Factor Ⅱ(FⅡ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for detecting rat prothrombin/coagulation factor II | |
Rat Coagulation Factor X (FⅩ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for rat common coagulation pathway and FX level detection | |
Rat Prothrombin Fragment 1+2 (F1+2) ELISA Kit | BioReagent | Coagulation activation marker ELISA | Used for evaluating thrombin generation in rats | |
Mouse Coagulation Factor Ⅱ(FⅡ) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for detecting mouse prothrombin/coagulation factor II | |
Mouse Coagulation Factor X (F10) ELISA Kit | BioReagent | Coagulation pathway ELISA | Used for mouse FX detection and common pathway analysis |
7 FAQ
7.1 What is the difference between fibrinolytic proteases and anticoagulant proteases?
Fibrinolytic proteases mainly act on preformed fibrin clots, causing degradation or lysis. Anticoagulant proteases mainly affect the coagulation cascade, thrombin generation, or fibrin formation process. A sample may have both fibrinolytic and anticoagulant effects, but clot lysis and coagulation time should be tested separately in experimental design.
7.2 Can the fibrin plate method directly prove thrombolytic ability?
Not completely. The fibrin plate method is suitable for initial screening of fibrinolytic activity, but results are affected by sample diffusion, gel thickness, and incubation conditions. Thrombolytic ability still requires further validation using plasma clots, whole-blood clots, or animal thrombus models.
7.3 What is the difference between plasminogen-containing and plasminogen-free fibrin plates?
Plasminogen-containing plates can detect plasminogen-activating activity, such as urokinase-, streptokinase-, or staphylokinase-like activity. Plasminogen-free plates are more suitable for determining whether a sample can directly degrade fibrin. Combining the two plate systems allows distinction between direct and indirect fibrinolysis.
7.4 Why is fibrinogen degradation not equal to thrombolysis?
Fibrinogen is the soluble precursor before clot formation, whereas fibrin is the network structure after clot formation. Some proteases can degrade fibrinogen and make clot formation difficult, but they may not strongly dissolve preformed cross-linked fibrin thrombi.
7.5 What indicators should be prioritized when evaluating lumbrokinase or nattokinase?
Key indicators include fibrin plate lysis zones, plasma clot lysis rate, fibrinogen degradation bands, fibrinopeptide release, FDP or D-dimer changes, protease activity units, and batch-to-batch consistency. If the sample is a crude extract or fermentation product, total protein, purity, and background contaminating protease activity should also be tested.
7.6 Are PT, APTT, and TT all necessary in anticoagulation experiments?
If the research objective is the anticoagulant mechanism, PT, APTT, and TT are recommended together. PT reflects the extrinsic coagulation pathway, APTT reflects the intrinsic coagulation pathway, and TT more directly reflects the thrombin-fibrinogen conversion process. Together, they can preliminarily indicate the site of action.
Fibrinolytic protease research should evaluate thrombolysis, fibrin degradation, and anticoagulant effects in a layered manner. Fibrin plates are suitable for initial screening, clot lysis models are used for application validation, and fibrinogen degradation, FPA, FPB, PT, APTT, TT, and coagulation factor detection are used for mechanism differentiation. Only by clarifying whether a protease directly degrades fibrin, activates plasminogen, or inhibits the coagulation process can its application value in antithrombotic research be accurately assessed.
For more related articles, please see below:
[1] Roles and Mechanisms of Proteases in Respiratory and Vascular Diseases
危险品化学品经营许可证（带存储）